La Jolla Pharmaceutical Company (NASDAQ:LJPC) shares saw an uptick in trading volume on Friday . 1,233,406 shares changed hands during trading, an increase of 334% from the previous session’s volume of 284,138 shares.The stock last traded at $31.48 and had previously closed at $31.38.

Several brokerages recently issued reports on LJPC. J P Morgan Chase & Co began coverage on shares of La Jolla Pharmaceutical in a research report on Wednesday, August 30th. They set an “overweight” rating and a $36.00 price target on the stock. BidaskClub upgraded shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Chardan Capital reiterated a “buy” rating and set a $85.00 price target on shares of La Jolla Pharmaceutical in a research report on Tuesday, August 8th. Jefferies Group LLC reiterated a “buy” rating and set a $40.00 price target on shares of La Jolla Pharmaceutical in a research report on Tuesday, July 25th. Finally, Zacks Investment Research downgraded shares of La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. La Jolla Pharmaceutical has an average rating of “Buy” and an average target price of $51.00.

The stock has a 50-day moving average of $31.23 and a 200 day moving average of $30.74. The company’s market cap is $696.43 million.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.09). La Jolla Pharmaceutical had a negative net margin of 12,692.37% and a negative return on equity of 91.66%. During the same period last year, the business earned ($0.90) earnings per share. Analysts forecast that La Jolla Pharmaceutical Company will post ($4.99) earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in La Jolla Pharmaceutical by 26.4% in the first quarter. Vanguard Group Inc. now owns 662,285 shares of the biopharmaceutical company’s stock valued at $19,769,000 after buying an additional 138,155 shares in the last quarter. Jennison Associates LLC boosted its stake in La Jolla Pharmaceutical by 16.1% in the second quarter. Jennison Associates LLC now owns 2,053,467 shares of the biopharmaceutical company’s stock valued at $61,132,000 after buying an additional 285,254 shares in the last quarter. Sphera Funds Management LTD. boosted its stake in La Jolla Pharmaceutical by 117.1% in the first quarter. Sphera Funds Management LTD. now owns 110,000 shares of the biopharmaceutical company’s stock valued at $3,284,000 after buying an additional 59,323 shares in the last quarter. Teachers Advisors LLC boosted its stake in La Jolla Pharmaceutical by 12.4% in the fourth quarter. Teachers Advisors LLC now owns 25,390 shares of the biopharmaceutical company’s stock valued at $445,000 after buying an additional 2,791 shares in the last quarter. Finally, FMR LLC boosted its stake in La Jolla Pharmaceutical by 20.3% in the first quarter. FMR LLC now owns 3,294,435 shares of the biopharmaceutical company’s stock valued at $98,339,000 after buying an additional 556,334 shares in the last quarter.

WARNING: “La Jolla Pharmaceutical Company (LJPC) Sees Unusually-High Trading Volume” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/17/la-jolla-pharmaceutical-company-ljpc-sees-unusually-high-trading-volume.html.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Receive News & Stock Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related stocks with our FREE daily email newsletter.